DE3280128D1 - Modifiziertes vaccinia virus und verfahren zu dessen herstellung und verwendung. - Google Patents

Modifiziertes vaccinia virus und verfahren zu dessen herstellung und verwendung.

Info

Publication number
DE3280128D1
DE3280128D1 DE8282402380T DE3280128T DE3280128D1 DE 3280128 D1 DE3280128 D1 DE 3280128D1 DE 8282402380 T DE8282402380 T DE 8282402380T DE 3280128 T DE3280128 T DE 3280128T DE 3280128 D1 DE3280128 D1 DE 3280128D1
Authority
DE
Germany
Prior art keywords
production
vaccinia virus
modified vaccinia
modified
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8282402380T
Other languages
English (en)
Inventor
Enzo Paoletti
Dennis Panicali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26989200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3280128(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/334,456 external-priority patent/US4769330A/en
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of DE3280128D1 publication Critical patent/DE3280128D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE8282402380T 1981-12-24 1982-12-23 Modifiziertes vaccinia virus und verfahren zu dessen herstellung und verwendung. Expired - Lifetime DE3280128D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/334,456 US4769330A (en) 1981-12-24 1981-12-24 Modified vaccinia virus and methods for making and using the same
US06/446,824 US4603112A (en) 1981-12-24 1982-12-08 Modified vaccinia virus

Publications (1)

Publication Number Publication Date
DE3280128D1 true DE3280128D1 (de) 1990-04-12

Family

ID=26989200

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8282402380T Expired - Lifetime DE3280128D1 (de) 1981-12-24 1982-12-23 Modifiziertes vaccinia virus und verfahren zu dessen herstellung und verwendung.

Country Status (10)

Country Link
US (3) US4603112A (de)
EP (1) EP0083286B2 (de)
JP (1) JPH0671429B2 (de)
AU (1) AU561816B2 (de)
CA (1) CA1340624C (de)
DE (1) DE3280128D1 (de)
DK (1) DK173927B1 (de)
IL (1) IL67537A (de)
NZ (1) NZ202833A (de)
PH (1) PH22658A (de)

Families Citing this family (432)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5866383A (en) * 1982-11-30 1999-02-02 The United States Of America As Represented By The Department Of Health And Human Services In vitro ligation of foreign DNA into large eukaryotic viruses
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
US5338674A (en) * 1983-02-25 1994-08-16 Wright Stephen E Process for producing a vaccine for a pathogenic RNA virus and product thereof
US5830477A (en) * 1984-04-25 1998-11-03 Transgene S.A. Vaccine against rabies and process for preparation thereof
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
WO1985005376A1 (fr) * 1984-05-22 1985-12-05 Transgene S.A. Vecteurs d'expression du facteur ix et lignees cellulaires produisant le facteur ix actif
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4738846A (en) * 1984-08-30 1988-04-19 The Salk Institute For Biological Studies Vaccine for vesicular stomatitis virus
FR2571060B1 (fr) * 1984-10-03 1987-01-09 Centre Nat Rech Scient Nouveaux vecteurs de clonage et d'expression dans les cellules eucaryotes utilisant le virus de la vaccine
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5128128A (en) * 1985-07-29 1992-07-07 The Upjohn Company Virus vaccine
AU591145B2 (en) * 1985-07-29 1989-11-30 Pharmacia & Upjohn Company Virus vaccine with deletion of an antigen of the wild-type virus
US5275934A (en) * 1985-07-29 1994-01-04 The Upjohn Company Method of detecting viral infection in vaccinated animals
IL79880A0 (en) * 1985-08-29 1986-11-30 Inst Medical W & E Hall Recombinant virus
US5352575A (en) * 1985-10-04 1994-10-04 The Upjohn Company Pseudorabies virus protein
US6251634B1 (en) 1985-11-26 2001-06-26 Pharmacia & Upjohn Company Pseudorabies virus protein
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
EP0243029A1 (de) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Rekombinantes Vaccinia-Virus, das ein menschliches Retrovirus-Gen ausdrückt
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
JPH0695935B2 (ja) * 1986-07-31 1994-11-30 東燃株式会社 ワクチニアウイルス株
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
CA1322731C (en) * 1986-09-22 1993-10-05 Hisatoshi Shida Gene for a-type inclusion body of poxvirus
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
EP0261940A3 (de) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
ES2055687T3 (es) * 1986-10-08 1994-09-01 Upjohn Co Vacuna de virus.
US5348741A (en) * 1987-02-03 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Vector for recombinant poxvirus expressing rabies virus glycoprotein
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
WO1988006182A1 (en) * 1987-02-10 1988-08-25 Toa Nenryo Kogyo Kabushiki Kaisha Bovine leukemia virus vaccine prepared by using recombinant vaccinia virus
DE3852304T3 (de) * 1987-03-02 1999-07-01 Enzon Lab Inc Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
EP0347425B1 (de) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Rekombinant-mykobakterielle impfstoffe
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
DE3890874T1 (de) * 1987-08-28 1989-12-21 Health Research Inc Rekombinante avipoxviren
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
JPH084508B2 (ja) * 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5069901A (en) * 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
US5316931A (en) * 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US20030150019A1 (en) * 1988-02-26 2003-08-07 Large Scale Biology Corporation Monopartite RNA virus transformation vectors
US6284492B1 (en) 1988-02-26 2001-09-04 Large Scale Biology Corporation Recombinant animal viral nucleic acids
US6054566A (en) * 1988-02-26 2000-04-25 Biosource Technologies, Inc. Recombinant animal viral nucleic acids
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8821441D0 (en) * 1988-09-13 1988-10-12 Animal Health Inst Viral vectors
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
CA2089497A1 (en) * 1990-08-15 1992-02-16 Lendon Payne Self-assembling replication defective hybrid virus particles
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
AU8740491A (en) * 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
WO1992009704A1 (en) * 1990-11-29 1992-06-11 Diagnostic Hybrids, Inc. Method for in situ detection and identification of nucleic acid sequences
ES2287206T3 (es) * 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
DK0623172T3 (da) * 1992-01-13 2005-04-25 Virogenetics Corp Rekombinant Mareks sygdomsvirus-poxvirusvaccine
JPH09503920A (ja) 1993-11-18 1997-04-22 チロン ビアジーン，インコーポレイティド 条件致死遺伝子を利用する組成物及び方法
DK0758397T3 (da) * 1994-04-29 2005-10-10 Baxter Healthcare Sa Rekombinante poxvira med fremmede polynucleotider i essentielle regioner
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
ZA965586B (en) 1995-07-03 1997-01-31 Akzo Nobel Nv Coccidiosis poultry vaccine
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP0954593A1 (de) 1996-07-25 1999-11-10 Therion Biologics Corporation Rekombinantes pockenvirus für die immunsierung gegen tumorassoziierte antigene.
EP1860192A1 (de) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
WO1999019466A2 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
EP2210945B1 (de) 1998-01-14 2013-06-26 Novartis Vaccines and Diagnostics S.r.l. Antigene aus Neisseria meningitidis
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
EP2003201A3 (de) 1998-03-18 2008-12-31 Corixa Corporation Verbindungen und Verfahren für Therapie und Diagnose von Lungenkrebs
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6602499B1 (en) 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
AU761780B2 (en) 1998-05-01 2003-06-12 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
WO2000008051A2 (en) 1998-08-07 2000-02-17 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
WO2000034483A2 (en) 1998-12-08 2000-06-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
PT1141331E (pt) 1998-12-16 2008-12-22 Novartis Vaccines & Diagnostic Quinase dependente de ciclina humana (hpnqalre)
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
JP2002543769A (ja) 1999-04-02 2002-12-24 コリクサ コーポレイション 肺癌の治療および診断のための化合物および方法
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
ES2559317T3 (es) 1999-10-29 2016-02-11 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria
EP1248646B1 (de) * 1999-12-21 2008-02-13 Merial Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
DE60142772D1 (de) 2000-01-17 2010-09-23 Novartis Vaccines & Diagnostic Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
JP5502253B2 (ja) 2000-02-23 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030175700A1 (en) 2000-04-21 2003-09-18 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP1278541A1 (de) * 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Verbesserung der immunogenität bei der verwendung einer kombination von dns und vacciniavirus-vektor impfstoffen
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
MXPA02011486A (es) 2000-05-19 2004-01-26 Corixa Corp Tratamiento profilactico y terapeutico de enfermedades infecciosas, autoinmunes y alergicas con compuestos a base de mono y disacarido.
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
AU2001273149A1 (en) 2000-06-28 2002-01-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DE60131975T2 (de) * 2000-07-27 2008-12-18 The Trustees Of The University Of Pennsylvania Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
EP2277894A1 (de) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäure und Proteine von Gruppen A und B Streptokokken
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2001297872B2 (en) * 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US20020192675A1 (en) * 2001-02-02 2002-12-19 The University Of Rochester Methods of identifying regulator molecules
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
AU2002255995A1 (en) * 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
GB0109515D0 (en) * 2001-04-17 2001-06-06 Neg Micon As A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system
EP1515982A4 (de) 2001-05-09 2005-10-26 Corixa Corp Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
DE60236364D1 (en) 2001-10-11 2010-06-24 Angeletti P Ist Richerche Bio Hepatitis-c-virus-impfstoff
US20030214690A1 (en) * 2001-11-26 2003-11-20 Escuti Michael J. Holographic polymer photonic crystal
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
CA2469620A1 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
CA2860702C (en) 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
WO2004041997A2 (en) * 2002-05-01 2004-05-21 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
ATE504653T1 (de) 2002-08-07 2011-04-15 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
BR0314629A (pt) 2002-09-19 2005-08-02 Us Gov Health & Human Serv Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso
US20070224124A1 (en) * 2002-09-30 2007-09-27 University Of South Florida Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
WO2004032868A2 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
BR0315872A (pt) 2002-10-29 2006-07-18 Us Gov Health & Human Serv Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso
EP1562982B1 (de) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unerwartete oberflächenproteine in neisseria meningitidis
SI1589934T1 (sl) 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7217526B2 (en) * 2003-01-24 2007-05-15 University Of Massachusetts Medical School Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
CN1980571A (zh) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 禽类及禽蛋中表达的外源蛋白质
US8067535B2 (en) * 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
EP1606419A1 (de) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systeme und methoden zur erhohung der milchproduktion in tieren
EP2371380A1 (de) 2003-03-28 2011-10-05 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA Virus, der modifizierte HIV hülle, gag und pol gene exprimiert
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004092216A1 (en) * 2003-04-15 2004-10-28 Trangene S.A. Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
EP1897938B9 (de) 2003-07-21 2011-08-31 Transgene SA Polypeptid mit einer verbesserten Zytosindeaminase-Aktivität
EP1925626A1 (de) 2003-07-21 2008-05-28 Transgene S.A. Neue multifunktionelle Cytokine
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
US7763592B1 (en) * 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
JP2007525217A (ja) 2004-02-19 2007-09-06 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ レプチンプロモーター多型及びその使用
DK1736541T3 (da) 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
DE602005023629D1 (de) 2004-07-14 2010-10-28 Univ California Biomarker für den frühzeitigen nachweis von ovarialkarzinom
WO2006036291A2 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
EP1789552A2 (de) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Verfahren zur regulation der differenzierung und behandlung von multiplem myelom
DK1789438T3 (en) 2004-08-27 2015-07-20 Us Government Recombinant MVA viruses expressing MODIFIED env, gag and pol genes of HIV CLADE A / G, CLADE CLADE B AND C
BRPI0515520A (pt) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
WO2006032104A1 (en) 2004-09-23 2006-03-30 The University Of Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
EP1701165A1 (de) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutischer und diagnostischer Gebrauch von TKTL1 sowie seiner Inhibitoren und Aktivatoren
EP2392348A3 (de) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Impfstoffe gegen Chlamydieninfektion
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
KR20150036658A (ko) 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
EP1893636A2 (de) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis-c-virus-nukleinsäureimpfstoff
WO2007014169A2 (en) * 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
JP2009515529A (ja) 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
EP2441846A3 (de) 2006-01-09 2012-07-25 The Regents Of the University of California Immunstimulierende Kombinationen aus TNFRSF, TLR, NLR, RHR, purinergischem Rezeptor, und Zytokin-Rezeptor-Antagonisten für Impfstoffe und die Tumorimmuntherapie
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
BRPI0708865A8 (pt) 2006-03-14 2019-01-22 Univ Oregon Health & Science métodos para produzir uma resposta imune à tuberculose
JP2009531464A (ja) 2006-03-29 2009-09-03 メリアル リミテッド 連鎖球菌に対するワクチン
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
US20100092471A1 (en) * 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008091311A1 (en) 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians
RU2482189C2 (ru) 2007-01-30 2013-05-20 Трансген С.А. Полипептиды е2 папилломавируса, применяемые для вакцинации
EP2125868B1 (de) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyurie-polypeptide und verwendungsverfahren
EP2139447A2 (de) * 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
EP2136778A2 (de) * 2007-03-20 2009-12-30 Harold Brem Wachstumsfaktorvermittelte kosmezeutika und ihre verwendung zur verbesserung der hautqualität
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP3539567A1 (de) 2007-07-02 2019-09-18 Etubics Corporation Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen
AU2008274906B2 (en) * 2007-07-12 2013-11-07 Oral Health Australia Pty Ltd Biofilm treatment
NZ582438A (en) 2007-07-12 2012-03-30 Oral Health Australia Pty Ltd A composition for use in raising an immune response to p. gingivalis
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
EP2274437B1 (de) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
BRPI0915605B8 (pt) 2008-05-08 2021-09-08 The Government Of The Us Secretary Of The Dept Of Healt & Human Services Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
CN102203121A (zh) 2008-08-29 2011-09-28 口腔健康澳洲私人有限公司 牙龈卟啉单胞菌感染的预防、治疗和诊断
WO2010042942A2 (en) 2008-10-10 2010-04-15 Children's Medical Center Corporation Biochemically stabilized hiv-1 env trimer vaccine
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2358757B1 (de) 2008-11-18 2018-09-12 Beth Israel Deaconess Medical Center Antivirale impfstoffe mit erhöhter zellimmunogenität
MX2011007494A (es) 2009-01-13 2011-08-12 Transgene Sa Uso de una fraccion de la mitocondria de acidos nucleicos de saccharomyces cerevisiae para la estimulacion inmune.
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
MX337287B (es) 2009-07-10 2016-02-22 Transgene Sa Biomarcador para seleccionar pacientes y metodos relacionados.
PL3210622T3 (pl) 2009-08-21 2021-06-28 Boehringer Ingelheim Animal Health USA Inc. Szczepionka z rekombinowanym paramyksowirusem ptaków oraz sposób jej wytwarzania i zastosowania
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2502076B1 (de) 2009-11-20 2018-04-18 Oregon Health and Science University Verfahren zum erkennen einer infektion mit dem mycobakterium tuberculosis
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
CA2792118C (en) 2010-03-12 2022-07-12 Merial Limited Bluetongue virus recombinant vaccines and uses thereof
EP3900740A1 (de) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenzavirusimpfstoffe und verwendungen davon
JP5913316B2 (ja) 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
KR102104650B1 (ko) 2011-03-21 2020-04-24 알티뮨 인크. 급속 및 지속적 면역학적제제-치료제
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JP6415977B2 (ja) 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
WO2012149038A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
EP2714077B1 (de) 2011-06-01 2018-02-28 Merial, Inc. Nadellose verabreichung von prrsv-impfstoffen
EP2723365A1 (de) 2011-06-21 2014-04-30 Oncofactor Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
WO2013012446A1 (en) 2011-07-20 2013-01-24 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
DK2741740T3 (en) 2011-08-12 2017-06-06 Merial Inc VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033260A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
EA201490659A1 (ru) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин Вакцины против вируса гриппа и их применения
WO2013082327A1 (en) 2011-11-30 2013-06-06 Merial Limited Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
EP2788477A2 (de) 2011-12-07 2014-10-15 Institut Pasteur Identifizierung des porcinen parecho-like virus und anwendungen
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2711878T3 (es) 2012-03-20 2019-05-08 Merial Inc Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
PT2844282T (pt) 2012-05-04 2019-07-23 Pfizer Antigénios associados à próstata e regimes de imunoterapêutica baseados em vacinas
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
KR20150058152A (ko) 2012-07-10 2015-05-28 트랜스진 에스아이 마이코박테리아 항원 백신
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
MX2015008815A (es) 2013-01-07 2016-10-26 Beth Israel Deaconess Medical Ct Inc Vacunas de trimero del envolvente (env) del virus de la inmunodeficiencia humana (vih) estabilizadas y metodos de usarlas.
EP2958586B1 (de) 2013-02-21 2018-09-05 Boehringer Ingelheim Vetmedica GmbH H5-proteine aus dem h5n1-influenzavirus zur verwendung als arzneimittel
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP2970410B1 (de) 2013-03-15 2020-01-22 The Regents of The University of California Mitochondrienderiviertes peptid mots3 als regler des stoffwechsels und des überlebens von zellen
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
CN105392882A (zh) 2013-04-19 2016-03-09 加利福尼亚大学董事会 孤星病毒
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
EP3695841A3 (de) 2013-07-01 2020-11-04 The Research Foundation for the State University of New York Ship-hemmung gegen fettleibigkeit
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3666790A1 (de) 2013-10-04 2020-06-17 Beth Israel Deaconess Medical Center, Inc. Stabilisierte humane immundefizienzvirus-c-hüllen-trimer-impfstoffe und verfahren zur verwendung davon
WO2015054427A1 (en) 2013-10-10 2015-04-16 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
CN112316129A (zh) 2014-04-03 2021-02-05 勃林格殷格翰动物保健美国有限公司 猪流行性腹泻病毒疫苗
WO2015200070A1 (en) 2014-06-17 2015-12-30 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
WO2015200833A2 (en) 2014-06-27 2015-12-30 Abbott Laboratories COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)
AP2017009846A0 (en) 2014-09-26 2017-03-31 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MX2017005687A (es) 2014-11-03 2017-08-21 Merial Inc Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (de) 2014-12-19 2020-12-30 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
JP2018523993A (ja) 2015-06-23 2018-08-30 メリアル インコーポレイテッド Ｐｒｒｓｖ微量タンパク質含有組換えウイルスベクター並びにその作製及び使用方法
CN107250346B (zh) * 2015-06-30 2019-11-15 希森美康株式会社 细胞保存液及其利用、以及细胞保存液的制造方法
BR112017028224A2 (pt) 2015-08-31 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
JP2018526454A (ja) 2015-09-16 2018-09-13 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタコレラ菌−ネズミチフス菌ワクチン
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
WO2017087550A1 (en) 2015-11-16 2017-05-26 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
MD3390430T2 (ro) 2015-12-15 2019-12-31 Janssen Vaccines & Prevention Bv Antigenele virusului imunodeficienței umane, vectori, compoziții și metode de utilizare ale acestora
CN109071592B (zh) 2016-01-08 2022-07-19 吉奥瓦科斯公司 用于产生对肿瘤相关抗原的免疫应答的组合物和方法
BR112018013967A2 (pt) 2016-01-19 2019-02-05 Pfizer vacinas contra o câncer
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
WO2017210181A1 (en) 2016-05-30 2017-12-07 Geovax Inc. Compositions and methods for generating an immune response to hepatitis b virus
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
CN110494159A (zh) 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
EA201990715A1 (ru) 2016-09-15 2019-08-30 Янссен Вэксинс Энд Превеншн Б.В. Стабилизирующие тример мутации белка оболочки hiv
CN109790550B (zh) 2016-09-20 2024-02-09 勃林格殷格翰动物保健有限公司 新颖的启动子
TW201823465A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 新穎豬流感疫苗
HUE064133T2 (hu) 2016-09-20 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Kutya adenovírus vektor
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
AU2017353378B2 (en) 2016-11-03 2024-03-14 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus
HUE061972T2 (hu) 2016-11-03 2024-02-28 Boehringer Ingelheim Vetmedica Gmbh Vakcina sertés parvovirus és sertés reprodukciós és légzõszervi szindróma vírus ellen, és eljárások ezek elõállítására
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3046684A1 (en) 2017-01-30 2018-08-02 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP2020517271A (ja) 2017-04-22 2020-06-18 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 改良ｌａｍｐ構築物
JP7222915B2 (ja) 2017-05-02 2023-02-15 イミュノミック セラピューティックス， インコーポレイテッド 癌抗原を含む改善されたｌａｍｐ構築物
JP7272965B2 (ja) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
CN111065406A (zh) 2017-06-21 2020-04-24 特兰斯吉恩股份有限公司 个性化疫苗
RU2020100072A (ru) 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert
CN110869047A (zh) 2017-07-12 2020-03-06 勃林格殷格翰动物保健美国有限公司 塞内卡病毒a免疫原性组合物及其方法
BR112020000867A2 (pt) 2017-07-19 2020-07-21 Janssen Vaccines & Prevention B.V. mutações da proteína do envelope do hiv estabilizando o trímero
KR20200041897A (ko) 2017-08-01 2020-04-22 에이비 스튜디오 인코포레이티드 이중특이 항체 및 그의 용도
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
TW201923084A (zh) 2017-09-23 2019-06-16 德商百靈佳殷格翰維美迪加股份有限公司 副黏液病毒科(paramyxoviridae)表現系統
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
US10864263B2 (en) 2017-11-20 2020-12-15 Janssen Pharmaceuticals, Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
JP7479281B2 (ja) 2017-11-24 2024-05-08 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｏｘ４０抗体及びその用途
JP7448954B2 (ja) 2018-02-21 2024-03-13 ザ ユニバーシティー オブ モンタナ ジアリールトレハロース化合物及びその使用
WO2019162294A1 (en) 2018-02-23 2019-08-29 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
IL276675B2 (en) 2018-02-23 2023-10-01 Eucure Beijing Biopharma Co Ltd Anti-PD-1 antibodies and uses thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
MX2020009722A (es) 2018-03-19 2021-01-29 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion ul43 de ehv.
EP3768307A1 (de) 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH Neue ehv mit inaktiviertem ul18 und/oder ul8
WO2019191005A1 (en) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
CA3105875A1 (en) 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
KR20210062026A (ko) 2018-09-12 2021-05-28 유큐(베이징) 바이오파마 코., 엘티디 항-tnfrsf9 항체 및 그의 용도
US10905758B2 (en) 2018-09-20 2021-02-02 Boehringer Ingelheim Vetmedica Gmbh Intranasal vector vaccine against porcine epidemic diarrhea
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
SG11202105153RA (en) 2018-11-19 2021-06-29 Biocytogen Pharmaceuticals Beijing Co Ltd Anti-pd-1 antibodies and uses thereof
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CN112400022B (zh) 2019-02-18 2023-06-30 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
KR20220018503A (ko) 2019-05-23 2022-02-15 더 유니버시티 오브 몬타나 Tlr 수용체 리간드에 기반한 백신 애주번트
US20240108703A1 (en) 2019-10-18 2024-04-04 Immunomic Therapeutics, Inc. Improved LAMP Constructs Comprising Cancer Antigens
PE20221182A1 (es) 2019-11-18 2022-08-05 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP3842065A1 (de) 2019-12-23 2021-06-30 Transgene Verfahren zum entwurf eines rekombinanten pockenvirus für einen therapeutischen impfstoff
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
WO2021158878A1 (en) 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4114925A1 (de) 2020-03-04 2023-01-11 Bioeclipse Therapeutics, Inc. Verfahren zur herstellung aktivierter immunzellen
EP4135757A1 (de) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma- und steap1-impfstoffe und ihre verwendungen
EP4158034A4 (de) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals Beijing Co Ltd Genetisch modifizierte nichtmenschliche tiere mit gemeinsamem immunglobulinlocus mit leichter kette
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
EP4175721A1 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
BR112023006274A2 (pt) 2020-10-05 2023-05-09 Boehringer Ingelheim Vetmedica Gmbh Proteína de fusão útil para vacinação contra rotavírus
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023194913A1 (en) 2022-04-05 2023-10-12 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4113712A (en) * 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
US4129646A (en) * 1976-11-02 1978-12-12 Merck & Co., Inc. Isolating hepatitis B Dane particles
US4088748A (en) * 1976-11-02 1978-05-09 Merck & Co., Inc. Hepatitis B surface antigen
US4162192A (en) * 1978-09-28 1979-07-24 Juridical Foundation Method for purification of HBs antigen
NZ192465A (en) * 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4322499A (en) * 1978-12-22 1982-03-30 The Regents Of The University Of California Adrenocorticotropin-lipotropin precursor gene
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0074808A3 (de) * 1981-09-16 1984-07-04 University Patents, Inc. Rekombinantes Verfahren und Materialien
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus

Also Published As

Publication number Publication date
EP0083286B1 (de) 1990-03-07
JPS58129971A (ja) 1983-08-03
IL67537A (en) 1986-02-28
EP0083286A3 (en) 1984-11-14
AU9180682A (en) 1983-06-30
IL67537A0 (en) 1983-05-15
US4603112A (en) 1986-07-29
DK173927B1 (da) 2002-02-25
AU561816B2 (en) 1987-05-21
DK572482A (da) 1983-06-25
US5972597A (en) 1999-10-26
EP0083286B2 (de) 1999-04-14
PH22658A (en) 1988-11-14
NZ202833A (en) 1986-03-14
EP0083286A2 (de) 1983-07-06
CA1340624C (en) 1999-07-06
US5583028A (en) 1996-12-10
JPH0671429B2 (ja) 1994-09-14

Similar Documents

Publication Publication Date Title
DE3280128D1 (de) Modifiziertes vaccinia virus und verfahren zu dessen herstellung und verwendung.
DE3581563D1 (de) Polysiloxanpfropfcopolymer und verfahren zu dessen herstellung.
DE3780560D1 (de) Fuehler und verfahren zu dessen herstellung.
DE3581998D1 (de) Ultraviolettstrahlungsdetektor und verfahren zu dessen herstellung.
DE3582576D1 (de) Dithioketo-pyrrolo-pyrrole, verfahren zu deren herstellung und verwendung.
DE3585171D1 (de) Mehrschichtstoff und verfahren zu dessen herstellung.
DE3784612D1 (de) Thermistor und verfahren zu seiner herstellung.
DE3688604D1 (de) Optisches geraet und verfahren zu dessen herstellung.
DE3670483D1 (de) 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung.
DE3775614D1 (de) Teilchenzaehler und verfahren zu dessen herstellung.
DE3582110D1 (de) Verdickungsmittel, verfahren zur herstellung und ihre verwendung.
DE3485628D1 (de) Kupferartiger katalysator und verfahren zu dessen herstellung.
DE3684654D1 (de) Elektrochemisches element und verfahren zu seiner herstellung.
DE3583912D1 (de) Feuchtigkeitsfuehler und verfahren zu dessen herstellung.
DE3677740D1 (de) 2-iod-perfluor-2-methylalkane, verfahren zu deren herstellung und deren verwendung.
DE3677812D1 (de) Polyhydroxypolyether, verfahren zu ihrer herstellung und ihre verwendung.
DE3580783D1 (de) Polyester und verfahren zu dessen herstellung.
DE3668948D1 (de) Hitzebestaendiges bauteil und verfahren zu dessen herstellung.
DE3484137D1 (de) Schnappscheibenzustandsfuehler und verfahren zu dessen herstellung.
PT72603A (de) Getterkorper und verfahren zu dessen herstellung
DE3483998D1 (de) Magnesiaklinker und verfahren zu seiner herstellung.
DE3574694D1 (de) Aufreissbares dosenteil sowie verfahren und vorrichtung zu dessen herstellung.
DE3585852D1 (de) Faerbematerial und verfahren zu dessen herstellung.
DE3770795D1 (de) Radierer und verfahren zu dessen herstellung.
LU79490A1 (de) Leucinreiches 3,1-s-a2-glykoprotein,verfahren zu dessen herstellung sowie dessen verwendung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings